Skip Nav Destination
1-20 of 20
Iain C. Macdougall, Amy M. Meadowcroft, Allison Blackorby, Borut Cizman, Alexander R. Cobitz, Sergio Godoy, Vivekanand Jha, Kirsten L. Johansen, Gearoid McMahon, Gregorio T. Obrador, Muh Geot Wong, Ajay K. Singh
Am J Nephrol (2023) 54 (1-2): 1–13.
Published Online: 23 May 2023
... treatment. Methods: ASCEND-D (NCT02879305) recruited 2,964 chronic dialysis patients receiving ESA treatment (standardized to weekly intravenous [IV] epoetin) who were iron replete at baseline. The primary ESA hyporesponsiveness definition was an ESA Resistance Index (ERI, ESA units/kg/week/hemoglobin g/L...
Sishir Gang, Prakash Khetan, Deepak Varade, Venkata Ramakrishna Chinta, Siddharth Mavani, Umesh Gupta, S. Venkata Krishna Reddy, Sunil Rajanna, Tarun Jeloka, Vivek Ruhela, Kevinkumar Kansagra, Pooja Kanani, Jayesh Bhatt, Kuldipsinh Zala, Study Investigator Group
Am J Nephrol (2022) 53 (5): 343–351.
Published Online: 22 April 2022
..., active-controlled clinical study conducted across 38 centers in India. A total of 392 patients with clinical diagnosis of anemia due to CKD with dialysis need (Erythrocyte Stimulating Agent [ESA] naïve or prior ESA users) and with baseline hemoglobin levels of 8.0–11.0 g/dL (inclusive) were randomized...
Dhananjai Agrawal, Deepak Varade, Hardik Shah, Alm Nazar, Jayakumar Krishnan, Vineet Shukla, Chinta Ramakrishna, Mahel Chinthana Bandara Galahitiyawa, Sidhharth B. Mavani, Sunil Rajanna, Petkar Jikki, Shamila De Silva, Vivek Ruhela, Parshottam Koradia, Kevinkumar Kansagra, Pooja Kanani, Nitin Sharma, Kuldipsinh Zala, Deven Parmar, Study Investigator Group
Am J Nephrol (2022) 53 (5): 352–360.
Published Online: 22 April 2022
... with a clinical diagnosis of anemia due to CKD without dialysis need and with baseline hemoglobin of 7.0–10.0 g/dL (inclusive) were randomized in a 1:1 ratio to receive either desidustat 100 mg oral tablets thrice a week for 24 weeks or biosimilar darbepoetin subcutaneous injection 0.75 μg/kg once in 2 weeks...
Am J Nephrol (2021) 52 (9): 702–713.
Published Online: 08 October 2021
... in nondialysis-dependent (NDD) CKD patients treated with traditional erythropoiesis-stimulating agents (ESAs) evaluated dosing trends of roxadustat and darbepoetin alfa (DA) required to maintain target hemoglobin concentrations in patients with risk factors associated with ESA hyporesponsiveness. Methods...
Bin Zhu, Wen-hua Liu, Dong-rong Yu, Yi Lin, Qiang Li, Meng-li Tong, Ya-yu Li, Ru-chun Yang, Yuan-yuan Du, Xuan-li Tang, Fei Jiang, Dan Fei, Xin-yi Wei, Fei-fei Zhang, Jia-zhen Yin, Wen-rong Wang, Xian-fa Li, Yue Sun, Yong-zhong Zhong, Mei-juan Zhang, Xiao-Xia Cheng, Cai-feng Zhu, Hong-yu Chen
Am J Nephrol (2020) 51 (8): 624–634.
Published Online: 21 July 2020
...: To investigate the relationship between hemoglobin levels and the progression of IgA nephropathy (IgAN). Methods: In a two-center cohort of 1,828 cases with biopsy-proven IgAN, we examined the association of hemoglobin levels with the primary outcome of a composite of all-cause mortality or kidney failure...
Am J Nephrol (2019) 50 (4): 272–280.
Published Online: 05 September 2019
...Takashi Hara; Miho Kimachi; Tatsuyoshi Ikenoue; Tadao Akizawa; Shunichi Fukuhara; Yosuke Yamamoto Background: Ultrafiltration during hemodialysis (HD) causes hemoconcentration. Little is known about the relationships between intra-dialytic changes in hemoglobin concentration and cardiovascular...
Deven V. Parmar, Kevinkumar A. Kansagra, Jatin C. Patel, Shuchi N. Joshi, Nitin S. Sharma, Apeksha D. Shelat, Nirav B. Patel, Vishal B. Nakrani, Farheen A. Shaikh, Harilal V. Patel, on behalf of the ZYAN1 Trial Investigators
Am J Nephrol (2019) 49 (6): 470–478.
Published Online: 21 May 2019
... in fasting conditions. The primary endpoint was change in hemoglobin (Hb) from baseline to week 6. Results: Baseline demographics were well balanced among all the treatment arms. In the modified intent-to-treat (mITT) population, a mean Hb increase of 1.57, 2.22, and 2.92 g/dL in Desidustat 100, 150, and 200...
Carola-Ellen Kleine, Melissa Soohoo, Omesh N. Ranasinghe, Christina Park, Maria V. Marroquin, Yoshitsugu Obi, Connie M. Rhee, Hamid Moradi, Csaba P. Kovesdy, Kamyar Kalantar-Zadeh, Elani Streja
Am J Nephrol (2018) 47 (5): 333–342.
Published Online: 18 May 2018
... dialysis initiation. Pre-end-stage renal disease (ESRD) factors like anemia management may impact early post-ESRD outcomes. Therefore, we evaluated the impact of pre-ESRD hemoglobin (Hgb) and pre-ESRD Hgb slope on post-ESRD mortality and hospitalization outcomes. Methods: The study included 31,472 veterans...
Finnian R. Mc Causland, Brian Claggett, Marc A. Pfeffer, Emmanuel A. Burdmann, Kai-Uwe Eckardt, Andrew S. Levey, John J.V. McMurray, Giuseppe Remuzzi, Ajay K. Singh, Scott D. Solomon, Robert D. Toto, Patrick Parfrey
Am J Nephrol (2018) 46 (6): 488–497.
Published Online: 14 December 2017
... is multifactorial and includes decreased production of erythropoietin (EPO), iron deficiency, inflammation, and EPO resistance. To better understand the trajectory of these parameters, we described temporal trends in hemoglobin (Hb), ferritin, transferrin saturation, C-reactive protein (CRP), and darbepoetin dosing...
Keiichi Sumida, Charles Dyer Diskin, Miklos Z. Molnar, Praveen K. Potukuchi, Fridtjof Thomas, Jun Ling Lu, Connie M. Rhee, Elani Streja, Kunihiro Yamagata, Kamyar Kalantar-Zadeh, Csaba P. Kovesdy
Am J Nephrol (2017) 46 (5): 397–407.
Published Online: 07 November 2017
...Keiichi Sumida; Charles Dyer Diskin; Miklos Z. Molnar; Praveen K. Potukuchi; Fridtjof Thomas; Jun Ling Lu; Connie M. Rhee; Elani Streja; Kunihiro Yamagata; Kamyar Kalantar-Zadeh; Csaba P. Kovesdy Background: Hemoglobin variability (Hb-var) has been associated with increased mortality both in non...
Tadao Akizawa, Yoshiharu Tsubakihara, Masaomi Nangaku, Yukihiro Endo, Hiromu Nakajima, Tomoko Kohno, Yukiko Imai, Natsumi Kawase, Katsutoshi Hara, John Lepore, Alexander Cobitz
Am J Nephrol (2017) 45 (2): 127–135.
Published Online: 16 December 2016
... for treatment of anemia associated with chronic kidney disease (CKD). The effect of daprodustat in Japanese CKD patients with anemia has not been previously investigated. Methods: We evaluated the relationship between daprodustat dose and hemoglobin response in Japanese patients on hemodialysis (HD) with anemia...
James B. Wetmore, Yi Peng, Keri L. Monda, Allyson M. Kats, Deborah H. Kim, Brian D. Bradbury, Allan J. Collins, David T. Gilbertson
Am J Nephrol (2015) 41 (4-5): 354–361.
Published Online: 17 June 2015
... (RBC) transfusions in peritoneal dialysis (PD) and hemodialysis (HD) patients. We sought to compare patterns of erythropoiesis-stimulating agents (ESA) and intravenous (IV) iron use, achieved hemoglobin levels, and RBC transfusion use in PD and HD patients. Methods: In quarterly cohorts of prevalent...
Am J Nephrol (2015) 41 (3): 183–190.
Published Online: 08 April 2015
... lower basal hemoglobin (11 ± 2 vs. 13 ± 2 g/dl, p < 0.001) and serum sodium (139 ± 2 vs. 140 ± 2 mmol/l, p < 0.05) than those with normonatremia. Multivariate logistic regression after adjustment for basal serum sodium showed that advanced age (OR 1.15; 95% CI 1.03-1.27) and lower hemoglobin level...
Junichi Hoshino, Rajnish Mehrotra, Connie M. Rhee, Kunihiro Yamagata, Yoshifumi Ubara, Kenmei Takaichi, Csaba P. Kovesdy, Miklos Z. Molnar, Kamyar Kalantar-Zadeh
Am J Nephrol (2013) 37 (5): 413–420.
Published Online: 09 April 2013
...Junichi Hoshino; Rajnish Mehrotra; Connie M. Rhee; Kunihiro Yamagata; Yoshifumi Ubara; Kenmei Takaichi; Csaba P. Kovesdy; Miklos Z. Molnar; Kamyar Kalantar-Zadeh Background: Although hemoglobin A1c (HbA1c) has been widely used as a clinical assessment tool for outcome analyses related to glycemic...
Uyen Duong, Kamyar Kalantar-Zadeh, Miklos Z. Molnar, Joshua J. Zaritsky, Isaac Teitelbaum, Csaba P. Kovesdy, Rajnish Mehrotra
Am J Nephrol (2012) 35 (2): 198–208.
Published Online: 26 January 2012
.... In our present study, we examined the association between prescribed ESA dose and mortality in peritoneal dialysis (PD) and hemodialysis (HD) patients. We hypothesized that PD patients received lower ESA dose for the same achieved hemoglobin compared to HD patients and that ESA dose-mortality...
Luca De Nicola, Roberto Minutolo, Paolo Chiodini, Pasquale Zamboli, Bruno Cianciaruso, Felice Nappi, Simona Signoriello, Giuseppe Conte, Carmine Zoccali, SIN-TABLE CKD Study Group
Am J Nephrol (2010) 32 (6): 533–540.
Published Online: 28 October 2010
... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Survival Anemia Hemoglobin Chronic kidney disease End-stage renal disease Clinical practice guidelines for management of adult non-dialysis chronic kidney disease...
Am J Nephrol (2009) 30 (6): 491–498.
Published Online: 29 September 2009
...David T. Gilbertson; Yi Peng; Brian Bradbury; James P. Ebben; Allan J. Collins Background/Aims: Hemoglobin level variability in hemodialysis patients is common, and has been associated with comorbidity, intercurrent illness, and mortality risk. We aimed to describe the influence of anemia...
Bruce Spinowitz, Daniel W. Coyne, Charmaine E. Lok, Mario Fraticelli, Maher Azer, Sanjay Dalal, Giuseppe Villa, Steven Rosansky, Helena Adamis, Ulrich Beyer
Am J Nephrol (2008) 28 (2): 280–289.
Published Online: 13 November 2007
... every 2 weeks (Q2W) via subcutaneous or intravenous injection using pre-filled syringes, for maintaining hemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis who converted directly from epoetin therapy. Methods: Patients (n = 336) were randomized 1:1 to continue epoetin...
Am J Nephrol (2004) 24 (5): 522–526.
Published Online: 01 December 2004
... Hemoglobin Renal failure End-stage renal disease (ESRD) in diabetes mellitus patients has been called a ‘medical catastrophe’ of worldwide dimension [ 1 ]. World Health Organization statistics identify 150 million people with diabetes mellitus worldwide and suggest that this figure may double...
Am J Nephrol (1998) 18 (6): 498–503.
Published Online: 09 December 1998
... 1 month (group 1, n = 32), or did not receive ACE inhibitors (group 2, n = 143). Patients with infections or overt iron deficiency were excluded. Total weekly EPO doses and hematocrit (Hct)/hemoglobin (Hgb) values in the two groups were compared. Variables known to affect response to EPO were...